Skip to content

Efficacy of memantine in acute stroke patients

Comparing the effectiveness of memantine with routine treatment in the prognosis of acute stroke patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211017052786N7
Enrollment
60
Registered
2025-10-17
Start date
2025-11-21
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke (cerebral infarction). Cerebral infarction

Interventions

Intervention 1: Control group: A group of acute stroke patients who received the routine treatment of this complication, the routine and usual treatment includes drugs such as statin and aspirin or wa

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients of both genders with acute ischemic stroke (mild to moderate (15-1) or severe (<15) according to the NIHSS criteria must be determined) Acute stroke patients hospitalized during the last 3 hours

Exclusion criteria

Exclusion criteria: Making the patient hyperactive in response to memantine or any other drug The presence of acute or chronic kidney failure History of liver disease History of heart disease and severe myocardial infarction in the last 48 hours The presence of autoimmune diseases in the patient The presence of Alzheimer's disease or any dementia History of taking memantine in the last 6 months The patient's stroke is hemorrhagic Pregnancy and breastfeeding History of seizures

Design outcomes

Primary

MeasureTime frame
The score obtained in the NIHSS Scale. Timepoint: 30th, 60th and 90th day. Method of measurement: NIH stroke scale (NIHSS scale).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hossein Moradi Rafigh

Ghoum University of Medical Sciences

Amirmmr287@gamil.com+98 25 3885 6440

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026